europeanpharmaceuticalreviewAugust 14, 2017
Tag: NHS , multiple myeloma , SMC , PACE , Carfilzomib (Kyprolis)
The Scottish Medicines Consortium (SMC) has published advice accepting 3 new medicines for regular use by NHS Scotland.
Carfilzomib can increase overall survival and progression free survival compared to other current treatment options
Carfilzomib (Kyprolis) was accepted for use in combination with another medicine, dexamethasone, for the treatment of multiple myeloma. Carfilzomib was considered through SMC’s Patient and Clinician Engagement (PACE) process for medicines used for very rare conditions. Carfilzomib can increase overall survival and progression free survival compared to other current treatment options, and also has a more favourable side effect profile.
In the PACE meeting, patient groups and clinicians spoke of how multiple myeloma becomes resistant to treatment over time, so there is a need for different treatment options.
The committee did not recommend Ameluz for routine use by NHS Scotland. Ameluz is a gel which can be used to treat basal cell carcinoma unsuitable for surgical removal. The committee was unable to recommend the medicine as it was not considered to be cost effective when compared to other similar preparations.
Also accepted following consideration through PACE, was venetoclax (Venclyxto) which can be used in the treatment of chronic lymphocytic leukaemia. PACE participants highlighted that patients have limited options when initial treatments fail or are unsuitable. Ventoclax has the potential to offer patients a substantial reduction in symptoms and an improved quality of life. Desmopressin for the treatment of idiopathic nocturnal polyuria, a condition where people need to pass urine frequently during the night, was also accepted.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: